Benoît Tessoulin

Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma

Laëtitia Vercellino, Roberta Di Blasi, Salim Kanoun et al. · Blood Advances · 2020 · 404 citations · Full text

Medicine, Oncology, Cell Therapy +16

PRIMA-1Met induces myeloma cell death independent of p53 by impairing the GSH/ROS balance

Benoît Tessoulin, Géraldine Descamps, Philippe Moreau et al. · Blood · 2014 · 165 citations · Full text

Medicine, Cancer Biology, Oncology +14

Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial

Steven Le Gouill, Franck Morschhauser, David Chiron et al. · Blood · 2020 · 129 citations · Full text

Medicine, Hematology, Oncology +12

Description of neurotoxicity in a series of patients treated with CAR T-cell therapy

Cathérine Belin, Perrine Devic, Xavier Ayrignac et al. · Scientific Reports · 2020 · 119 citations · Full text

Life Sciences, Hematology, Oncology +15

Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma

Michael Wang, Wojciech Jurczak, Pier Luigi Zinzani et al. · Journal of Clinical Oncology · 2023 · 106 citations · Full text

Medicine, Hematology, Pharmacology +16